A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs ISIS CRPRx (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top